Level of evidence for therapeutic drug monitoring of everolimus;Évaluation du niveau de preuve du suivi thérapeutique pharmacologique de l'évérolimus

Therapie

Volumn 66, Issue 1, 2011, Pages 57-61

  Goirand, Françoise ^a   Royer, Bernard ^b   Hulin, Anne ^c   Saint Marcoux, Franck ^d  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Everolimus; Level of evidence; Monitoring; Therapeutic drug

Indexed keywords

EVEROLIMUS;

AREA UNDER THE CURVE; ARTICLE; DRUG EFFICACY; DRUG MONITORING; GRAFT REJECTION; HUMAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TOXICITY;

EID: 79954446560     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2010025     Document Type: Article

References (25)

1. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first posttransplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001; 69: 48-56. (Pubitemid 32108671)
2. Budde K, Neumayer HH, Lehne G, et al. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrol Dial Transplant 2004; 19: 2606-14. (Pubitemid 39360111)
3. Kovarik JM, Kaplan B, Silva HT, et al. Pharmacokinetics of an everolimuscyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant 2003; 3: 606-13. (Pubitemid 36612844)
4. Kovarik JM, Eisen H, Dorent R, et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant 2003; 22: 1117-25. (Pubitemid 37206567)
5. Mabasa VH, Ensom MH. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit 2005; 27: 666-76. (Pubitemid 41437646)
6. Le Guellec C, Simon N, Hulot JS, et al. Méthodologie pour l'évaluation du niveau de preuve du suivi thérapeutique pharmacologique. Evidence-based therapeutic drug monitoring: a systematic assessment. La lettre du pharmacologue 2009; 23(1): 21-5.
7. Korecka M, Shaw LM. Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. Ann Transplant 2009; 14: 61-72.
8. Baldelli S, Crippa A, Gabrieli R, et al. Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. Clin Biochem 2006; 39: 1152-9. (Pubitemid 44848323)
9. Salm P, Warnholtz C, Boyd J, et al. Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem 2006; 39: 732-8. (Pubitemid 44036785)
10. Kahan BD, Wong RL, Carter C, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1999; 68: 1100-6. (Pubitemid 29517697)
11. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43: 83-95. (Pubitemid 38283132)
12. Rothenburger M, Zuckermann A, Bara C, et al. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007; 26: 305-11. (Pubitemid 46498769)
13. Hummel M. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. J Heart Lung Transplant 2005; 24: S196-S200; discussion S10-1. (Pubitemid 40379798)
14. Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005; 19: 145-52. (Pubitemid 40424882)
15. Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532-40. (Pubitemid 39552941)
16. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521-30.
17. Kahan BD, Kaplan B, Lorber MI, et al. RADin de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001; 71: 1400-6.
18. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002; 73: 920-5. (Pubitemid 34252356)
19. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 2004; 26: 499-505. (Pubitemid 39314317)
20. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626-35. (Pubitemid 38523586)
21. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-58. (Pubitemid 37025404)
22. Starling RC, Hare JM, Hauptman P, et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004; 4: 2126-31. (Pubitemid 39611643)
23. Kovarik JM, Snell GI, Valentine V, et al. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant 2006; 25: 440-6.
24. Delgado JF, Manito N, Segovia J, et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev (Orlando) 2009; 23: 69-79.
25. Lehmkuhl H, Ross H, Eisen H, et al. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 2005; 37: 4145-9. (Pubitemid 43015978)